Save information for later
Sign Up

Learn About Wiskott-Aldrich Syndrome

What is the definition of Wiskott-Aldrich Syndrome?

Wiskott-Aldrich syndrome is characterized by abnormal immune system function (immune deficiency), eczema (an inflammatory skin disorder characterized by abnormal patches of red, irritated skin), and a reduced ability to form blood clots. This condition primarily affects males.

What are the causes of Wiskott-Aldrich Syndrome?

Mutations in the WAS gene cause Wiskott-Aldrich syndrome. The WAS gene provides instructions for making a protein called WASP. This protein is found in all blood cells. WASP is involved in relaying signals from the surface of blood cells to the actin cytoskeleton, which is a network of fibers that make up the cell's structural framework. WASP signaling triggers the cell to move and attach to other cells and tissues (adhesion). In white blood cells, this signaling allows the actin cytoskeleton to establish interactions between cells and the foreign invaders that they target (immune synapses).

How prevalent is Wiskott-Aldrich Syndrome?

The estimated incidence of Wiskott-Aldrich syndrome is between 1 and 10 cases per million males worldwide; this condition is rarer in females.

Is Wiskott-Aldrich Syndrome an inherited disorder?

This condition is inherited in an X-linked pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome, one of the two sex chromosomes in each cell. In males, who have only one X chromosome, a mutation in the only copy of the gene in each cell is sufficient to cause the condition. In females, who have two copies of the X chromosome, one altered copy of the gene in each cell can lead to less severe features of the condition or may cause no signs or symptoms at all. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Who are the top Wiskott-Aldrich Syndrome Local Doctors?
Andrew R. Gennery
Elite in Wiskott-Aldrich Syndrome
Elite in Wiskott-Aldrich Syndrome
Queen Victoria Road, 
Newcastle Upon Tyne, ENG, GB 

Andrew Gennery practices in Newcastle Upon Tyne, United Kingdom. Mr. Gennery is rated as an Elite expert by MediFind in the treatment of Wiskott-Aldrich Syndrome. His top areas of expertise are Primary Immunodeficiency (PID), Severe Combined Immunodeficiency (SCID), Chronic Granulomatous Disease, Bone Marrow Transplant, and Heart Transplant.

Fabio Ciceri
Elite in Wiskott-Aldrich Syndrome
Elite in Wiskott-Aldrich Syndrome
Milan, IT 

Fabio Ciceri practices in Milan, Italy. Mr. Ciceri is rated as an Elite expert by MediFind in the treatment of Wiskott-Aldrich Syndrome. His top areas of expertise are Leukemia, Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Wiskott-Aldrich Syndrome
Elite in Wiskott-Aldrich Syndrome
Milan, IT 

Alessandro Aiuti practices in Milan, Italy. Mr. Aiuti is rated as an Elite expert by MediFind in the treatment of Wiskott-Aldrich Syndrome. His top areas of expertise are Wiskott-Aldrich Syndrome, Adenosine Deaminase Deficiency, Metachromatic Leukodystrophy, Bone Marrow Transplant, and Splenectomy.

What are the latest Wiskott-Aldrich Syndrome Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Summary: This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.

Who are the sources who wrote this article ?

Published Date: December 01, 2019
Published By: National Institutes of Health